Bringing pharmacomicrobiomics to the clinic through well-designed studies
Name:
ClinicalTranslationalSci_2022_ ...
Size:
851.9Kb
Format:
PDF
Description:
Final Published Version
Affiliation
Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit College of PharmacyIssue Date
2022
Metadata
Show full item recordPublisher
John Wiley and Sons IncCitation
Steiner, H. E., Patterson, H. K., Giles, J. B., & Karnes, J. H. (2022). Bringing pharmacomicrobiomics to the clinic through well-designed studies. Clinical and Translational Science.Rights
Copyright © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Pharmacomicrobiomic studies investigate drug-microbiome interactions, such as the effect of microbial variation on drug response and disposition. Studying and understanding the interactions between the gut microbiome and drugs is becoming increasingly relevant to clinical practice due to its potential for avoiding adverse drug reactions or predicting variability in drug response. The highly variable nature of the human microbiome presents significant challenges to assessing microbes’ influence. Studies aiming to explore drug-microbiome interactions should be well-designed to account for variation in the microbiome over time and collect data on confounders such as diet, disease, concomitant drugs, and other environmental factors. Here, we assemble a set of important considerations and recommendations for the methodological features required for performing a pharmacomicrobiomic study in humans with a focus on the gut microbiome. Consideration of these factors enable discovery, reproducibility, and more accurate characterization of the relationships between a given drug and the microbiome. Furthermore, appropriate interpretation and dissemination of results from well-designed studies will push the field closer to clinical relevance and implementation. © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.Note
Open access journalISSN
1752-8054PubMed ID
35899413Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1111/cts.13381
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.
Related articles
- Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions.
- Authors: Aziz RK, Hegazy SM, Yasser R, Rizkallah MR, ElRakaiby MT
- Issue date: 2018 Oct
- Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery.
- Authors: Kamath S, Stringer AM, Prestidge CA, Joyce P
- Issue date: 2023 Jul-Dec
- Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment.
- Authors: Jia L, Huang S, Sun B, Shang Y, Zhu C
- Issue date: 2023
- The impact of common pharmaceutical excipients on the gut microbiota.
- Authors: Subramaniam S, Kamath S, Ariaee A, Prestidge C, Joyce P
- Issue date: 2023 Jul-Dec
- Interaction between drugs and the gut microbiome.
- Authors: Weersma RK, Zhernakova A, Fu J
- Issue date: 2020 Aug

